Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2025 07:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies

Initial data from the Phase 1 trial expected in 2025 SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology...
November 21, 2024 07:30 ET | Source: Global Market Insights Inc.

Blood Cancer Diagnostics Market to hit USD 22.2 billion by 2032, says Global Market Insights Inc.

Selbyville, Delaware, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Blood Cancer Diagnostics Market size was valued at approximately USD 12.4 billion in 2023 and is projected to grow at a CAGR of 6.8% between...
September 06, 2024 02:00 ET | Source: SPHERICAL INSIGHTS LLP

Global Hematologic Malignancies Market Size To Worth USD 144.58 Billion By 2033 | CAGR Of 7.97%

New York, United States , Sept. 06, 2024 (GLOBE NEWSWIRE) -- The Global Hematologic Malignancies Market Size is to Grow from USD 67.18 Billion in 2023 to USD 144.58 Billion by 2033, at a Compound...
April 11, 2023 08:30 ET | Source: Prelude Therapeutics, Inc.

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight...
March 15, 2023 08:00 ET | Source: Prelude Therapeutics, Inc.

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial...
March 01, 2021 10:47 ET | Source: Emergen Research

Hematologic Malignancies Testing Market Size Worth USD 5.45 Billion by 2027 | Increasing Research and Development Activities and Increasing Prevalence of Cancer are Significant Factors Influencing Industry Growth, says Emergen Research

Vancouver, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) -- The global Hematologic Malignancies Testing Market is forecasted to be worth USD 5.45 Billion by 2027, according to a current analysis...
March 01, 2021 10:47 ET | Source: Emergen Research

Hematologic Malignancies Testing Market Size Worth USD 5.45 Billion by 2027 | Increasing Research and Development Activities and Increasing Prevalence of Cancer are Significant Factors Influencing Industry Growth, says Emergen Research

Vancouver, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) -- The global Hematologic Malignancies Testing Market is forecasted to be worth USD 5.45 Billion by 2027, according to a current analysis...
May 21, 2019 06:00 ET | Source: Invivoscribe, Inc.

Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies

SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Invivoscribe, Inc., a vertically integrated global company focused on Improving Lives with Precision Diagnostics®, today announces expansion of space and...
February 04, 2019 08:55 ET | Source: INmune Bio, Inc.

INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “INMB”

LA JOLLA, CA, Feb. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s innate immune system...